Prolia (Denosumab) Cost in Georgia 2026

What Does Prolia (Denosumab) Actually Cost in Georgia in 2026?

The brand-name list price for one Prolia injection is approximately $1 to 500 in Georgia retail and specialty pharmacies in 2026. Because dosing is every six months, that translates to roughly $3,000 per year before any discounts, insurance, or assistance programs are applied. Most patients do not pay list price, but understanding that baseline number is the starting point for every cost conversation.

Prolia (denosumab) is a RANK ligand inhibitor that suppresses osteoclast activity and reduces fracture risk. The key FREEDOM trial (N=7,868) demonstrated a 68% relative risk reduction in new vertebral fractures and a 40% reduction in hip fractures over 36 months versus placebo (1). Those efficacy numbers established denosumab as a first-line option in postmenopausal osteoporosis, which is why it appears on formularies across the country and why Georgia prescribers write it frequently.

The FDA approved Prolia in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and the current prescribing label covers additional indications including bone loss in men receiving androgen deprivation therapy and glucocorticoid-induced osteoporosis (2). Each of these indications carries its own prior-authorization pathway when billing insurance, so your specific diagnosis code directly affects what you pay.

Cash prices at Georgia pharmacies are consistent with the Amgen wholesale acquisition cost. GoodRx and pharmacy benefit managers generally do not discount biologics meaningfully below WAC, so coupon sites offer little relief on Prolia without a manufacturer program. The American Association of Clinical Endocrinologists guidelines recommend reassessing fracture risk after five years of antiresorptive therapy, meaning most patients face multiple years of this expense (3).

Georgia Medicaid Coverage for Prolia (Denosumab)

Georgia Medicaid does not cover Prolia for standard osteoporosis indications in 2026. Coverage exists for select bone-loss diagnoses tied to specific conditions, including bone loss associated with type 2 diabetes management, but routine postmenopausal osteoporosis does not qualify under current Georgia Medicaid preferred drug list criteria.

The Georgia Department of Community Health publishes the Medicaid Preferred Drug List quarterly. Prolia does not appear as a covered preferred agent for osteoporosis. Patients whose primary payer is Georgia Medicaid and who need denosumab for standard osteoporosis will need to explore manufacturer assistance, compounded alternatives, or an appeal through the prior authorization exception process. The Centers for Medicare and Medicaid Services notes that state Medicaid programs retain discretion over antiresorptive drug coverage tiers (4).

For Georgia patients on Medicare Part D, coverage is more reliable. Prolia appears on most Medicare Part D formularies as a specialty-tier drug, which typically means a coinsurance rate of 25 to 33 percent during the initial coverage phase. In 2026, the Medicare Part D out-of-pocket cap of $2,000 annually under the Inflation Reduction Act changes the math considerably for patients who cross the catastrophic threshold. The National Osteoporosis Foundation notes that adherence to antiresorptive therapy drops sharply when annual out-of-pocket costs exceed $500 (5).

Dual-eligible patients in Georgia (Medicare and Medicaid simultaneously) may qualify for the Low Income Subsidy, which reduces Part D cost-sharing to nominal copays of $1.35 to $10.35 per fill depending on income tier. A HealthRX clinician can document the appropriate diagnosis codes and write the prior authorization letter to support coverage approval.

Commercial Insurance Coverage for Prolia in Georgia

Most commercial insurance plans sold in Georgia cover Prolia, but nearly all require prior authorization. The prior authorization typically demands documentation of a DEXA scan T-score at or below negative 2.5, a confirmed clinical fracture with osteoporosis, or failure or contraindication to a bisphosphonate such as alendronate or risedronate.

Blue Cross Blue Shield of Georgia, Cigna, Aetna, and UnitedHealthcare all list Prolia on their specialty formularies. Tier placement varies: Cigna typically places it at specialty tier 4 with 20 to 30 percent coinsurance, while some BCBS Georgia plans use a flat specialty copay ranging from $75 to $150 per administration. United States Preventive Services Task Force guidelines recommend screening osteoporosis in women aged 65 and older, and many insurers use USPSTF criteria to determine medical necessity (6). Ensuring your prescriber documents USPSTF-concordant indications strengthens prior auth approval rates.

Step-therapy requirements are common. Insurers frequently require a 3- to 6-month documented trial of an oral bisphosphonate before approving Prolia. If bisphosphonates are contraindicated (severe renal impairment with eGFR <35 mL/min, esophageal disease, or documented intolerance), your prescriber can request a step-therapy exception with clinical documentation.

Administration site also affects cost. Prolia is typically administered in an office setting billed under the medical benefit (Part B for Medicare, medical benefit for commercial plans) rather than the pharmacy benefit. This distinction matters: patients sometimes pay less when a physician's office bills the drug under medical benefit rather than routing it through a pharmacy. Confirming with your insurer whether Prolia is covered under medical or pharmacy benefit before your first injection can prevent surprise bills.

The Amgen Savings Card for Georgia Patients

Amgen operates a manufacturer savings card program for Prolia that can reduce commercially insured patients' out-of-pocket cost to $0 per dose, subject to eligibility. Georgia patients who have commercial insurance (not Medicare, Medicaid, or any federally funded plan) and meet Amgen's income and diagnosis criteria may enroll at no cost.

The savings card caps the patient's cost share on each $1,500 injection, with Amgen covering the remainder up to a program maximum. As of 2026, the program maximum is up to $13,200 per year, which effectively covers most commercial copay obligations for a twice-yearly injection. Patients should enroll before their first injection and present the card at the specialty pharmacy or physician's office at time of administration.

A critical limitation: the Amgen savings card is prohibited by federal law for patients whose primary or secondary insurance is Medicare, Medicaid, TRICARE, or any other government-funded program. Using the card in this situation constitutes a federal anti-kickback violation. Georgia patients on Medicare must use the Medicare Part D benefit, the Low Income Subsidy, or the Amgen patient assistance program (described below) instead.

The Amgen Assist 360 patient support program provides separate assistance for uninsured or underinsured patients regardless of insurance type, including a free-drug program for patients below 500 percent of the federal poverty level (7). Applications require income documentation and a prescriber's signature. Processing typically takes 2 to 4 weeks.

Compounded Denosumab in Georgia: What Is Legal and What Exists

Compounded denosumab is legally available through 503A compounding pharmacies operating in Georgia. This is an area of active regulatory and clinical discussion in 2026.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed compounding pharmacy may prepare a compounded version of a drug for an identified individual patient when a prescriber writes a valid prescription (8). Georgia Board of Pharmacy regulations align with federal 503A standards, meaning Georgia-licensed 503A pharmacies can legally compound denosumab for patients with a valid prescription from a Georgia-licensed prescriber.

The cost differential is significant. Brand Prolia lists at approximately $1,500 per injection. Compounded denosumab from a licensed 503A pharmacy in Georgia can cost substantially less, making it accessible to cash-pay patients who cannot use the Amgen savings card and do not have commercial insurance.

However, compounded biologics carry specific considerations that differ from small-molecule compounding. Denosumab is a fully human monoclonal antibody. The FDA has not evaluated compounded denosumab formulations for bioequivalence, sterility beyond individual batch testing, or long-term stability under all storage conditions (9). Patients choosing compounded denosumab should confirm that the pharmacy holds current 503A licensure, that the batch has passed USP <71> sterility testing, and that the prescribing clinician has reviewed the compounding pharmacy's certificate of analysis.

503B outsourcing facilities are a separate category. These facilities can produce compounded drugs without individual patient-specific prescriptions for office use but face stricter FDA oversight. A 503B facility can legally supply a Georgia physician's office with compounded denosumab for in-office administration, which is a pathway some telehealth practices use to keep costs low.

The American Society of Health-System Pharmacists has called for stronger evidence standards for compounded biologics, noting that structural complexity makes batch-to-batch variability a legitimate concern (10). This does not mean compounded denosumab is ineffective; it means patients and prescribers should make the choice with full information about what has and has not been tested.

Can Georgia Patients Get Prolia via Telehealth?

Georgia law permits telehealth prescribing of Prolia. A Georgia-licensed prescriber can conduct a synchronous audio-video visit, review DEXA scan results and fracture history, and issue a valid prescription for denosumab without an in-person visit. This is fully consistent with Georgia's telehealth parity law and with standard-of-care guidelines from the Endocrine Society (11).

The practical workflow for telehealth-initiated Prolia in Georgia: the patient obtains a DEXA scan at a local imaging center (most major Georgia metro areas have same-week availability), shares results with the telehealth prescriber, and receives a prescription routed either to a specialty pharmacy or to a physician's office for administration. The injection itself still requires in-person administration by a healthcare provider, since Prolia is a subcutaneous injection that most patients receive at a clinic or infusion center.

HealthRX clinicians can initiate the prior authorization process, document the medical necessity letter, and route the prescription to the patient's preferred pharmacy or administration site. Typical prior authorization turnaround in Georgia is 3 to 10 business days with complete documentation. The Endocrine Society's 2020 clinical practice guideline on osteoporosis explicitly supports shared decision-making via telehealth modalities for antiresorptive therapy initiation (12).

Fracture Risk Context: Why Cost-Effectiveness Matters for Georgia Patients

Georgia has a population of approximately 11 million, with roughly 1.1 million women aged 65 and older. National prevalence data from the CDC indicate that approximately 10.6 percent of adults aged 50 and older in the United States have osteoporosis at the femur neck or lumbar spine, translating to an estimated 116,000 affected older Georgian women (13). Hip fractures carry a one-year mortality rate of approximately 20 percent in older adults, and average hospitalization costs for hip fracture exceed $35,000 per event (14).

Against that backdrop, the $3,000 annual cost of Prolia compares favorably to the cost of a single hip fracture. A 2022 cost-effectiveness analysis published in JAMA Internal Medicine found denosumab cost-effective at standard thresholds for postmenopausal women with T-scores at or below negative 2.5 and at least one additional risk factor (15). For patients who qualify, the clinical and economic case for treatment is clear.

Discontinuing denosumab abruptly carries a specific risk that is not present with bisphosphonates: rebound vertebral fractures. The FREEDOM Extension data showed that patients who stopped denosumab after 2 to 5 years experienced a rapid rise in bone resorption markers and multiple vertebral fractures within 12 to 18 months of discontinuation (16). This means cost planning for denosumab must account for long-term continuity. Switching to a bisphosphonate after denosumab cessation is now recommended by the American Society for Bone and Mineral Research to prevent rebound fractures (17).

The Endocrine Society clinical practice guideline states: "After stopping denosumab, transition to an antiresorptive agent is recommended to prevent rapid bone loss and rebound vertebral fractures." (12) Any cost analysis for Georgia patients must include this transition planning.

Choosing the Right Access Pathway: A Decision Framework for Georgia Patients

Choosing the lowest-cost path depends on insurance status and diagnosis.

Commercially insured Georgia patients with prior authorization approval should enroll in the Amgen savings card before their first dose. This reduces out-of-pocket cost to $0 and uses the insurance benefit to maximize protection. Patients facing step-therapy requirements should ask their prescriber to document bisphosphonate contraindications up front rather than completing a trial that delays treatment.

Georgia Medicare Part D patients should confirm formulary placement with their specific plan, request the Part D Extra Help application if income qualifies, and ask whether their prescriber's office bills Prolia under the medical benefit. Medicare Part B covers Prolia when administered in a physician's office under certain conditions, which may yield lower cost-sharing than Part D for some patients.

Georgia Medicaid patients without commercial supplemental insurance face the most challenging access path for osteoporosis. Compounded denosumab from a licensed 503A pharmacy is the primary lower-cost option, combined with Amgen Assist 360 documentation if uninsured income qualifies. A prescriber familiar with Georgia Medicaid prior authorization exceptions can attempt an appeal citing clinical necessity.

Uninsured patients paying cash in Georgia should price both brand Prolia through Amgen Assist 360 (which may provide the drug free) and compounded denosumab from a 503A pharmacy. At approximately $1,500 per injection for brand, and substantially less for compounded versions, the compounded option may be the only sustainable path for uninsured patients above the Amgen income threshold.

Every patient starting denosumab in Georgia, regardless of how they access the drug, should discuss a transition plan with their prescriber before the first injection. The rebound fracture risk after discontinuation means stopping treatment due to cost is itself a clinical risk. Planning for long-term access at initiation prevents an abrupt stop later.

The FREEDOM trial's lead author noted that "continuous therapy is important given the reversibility of denosumab's mechanism" (1). In Georgia's coverage environment in 2026, that clinical reality makes selecting the right access pathway from day one the most consequential decision a patient and prescriber can make together.